Member Info for lukehere

Having that in mind, recent high flyer React Energy was provided with Nominated Adviser Services in a Reverse Takeover of an AIM quoted company by our newly appointed NOMAD,SPARK Advisory. Interesting ?

Nor me. In fact my best touch for 12 months. FITB is a real piece of work and should not be a quoted company imo. No longer holding but I will be back at sub .17 still hoping for future input from the "concert party".

https://www.smartpakequine.com/pt/outsmart-fly-spray-14237 It's great to see OutSmart relaunched as SmartPak are very keen on this TYRU product. The shares look attractive imo at just 2.0pence to buy at the close on Friday,particularly as the MMs were at the same moment bidding 1.875 pence for 500k . A bit risky maybe,yet a decent update could decisively turn sentiment.

All dreamers and chancers get it right, to a degree, once in a while stilolosses ; so good luck with your investments. Fortunately, some of us are constant our views.

An announcement is indeed forthcoming,probably the week after next. It was the CEO himself who has pencilled in the date and I have great faith in Mr Burnham's knowing more about the company than certain others. Why else would the demand for stock resurface ?

Good to see the Stilo share price moving off the bottom of its upward trend channel . Possibly this is in anticipation of an announcement from STL in early December regarding the further enhancement of its technology portfolio.

My posting was merely to flag up the increasingly competitive trading environment. A brief trawl through the internet will yield a plethora of specifics.

A "prominent player" it might be,yet there is growing competition,both in terms of innovative new products and competitively priced,longer lasting brands. If Opus is anything to go by then Sentek could have problems in remaining an earnings enhancing investment for SDI.

Over the six month timescale mentioned by icepick,we might just see news flow encouraging some upward movement in the TYRU share price.Listed below are a few of the candidates which imo could stimulate investor interest in the stock. TyraTech has a valuable technology portfolio , some elements of which are not currently core to their current strategic direction. If ,as planned,they are able to release this value,maybe in an area relating to domestic pets,via a trade sale,then any funds released would allow TYRU to further exploit their positions of strength in the personal care sector and to progress the opportunities in animal health, which they see as the larger opportunity over the longer term.Any sale proceeds would also serve to strengthen the weakish balance sheet. Out Smart could be successfully relaunched.Their distributor, SmartPak,believes that there is a great future for the product and are eager to recommence selling the reformulation. News of a reversal in the slowdown in the overall market for head lice products in the US, seen over the past two to three months, would certainly garner market approval. Tyratech could additionally provide an positive update on the progress of early PureScience sales and/or the new market for Vamousse etc in France. TYRU Directors might continue to express their confidence via further share buying. I would welcome ANY upward movement in the SP that is not subsequently surrendered.

The selling of STL stock has resulted in the SP falling back to its medium term upward trend line. Imo it is good to see the recent spike in the share price eradicated.

pwak. In fact a very good article. Thanks for the find. "Experts claim a genetic mutation of head lice in the US means the pests are becoming resistant to ordinary chemical treatments GP Dr Paul Stillman explains: “Super lice are head lice that have become more resistant to ordinary chemical treatments." The article includes his assertion that, “Treatments like Vamousse are effective on unhatched eggs as well as lice and only need to be used once.” As far as I can see,Vamousse is the ONLY treatment mentioned ! http://www.mirror.co.uk/the-people/super-lice-itching-cause-problems-8859987

Huge trading volumes reported way after the market close today,with significant premiums being paid to acquire stock.Hopefully this will prove to be a precursor to something of a recovery in the share price.

In their Broker Note today ,Allenby Capital stress the importance of the PS range ,stating that the market for these products may be substantially higher than for Vamousse,although lead times may prove longer. Allenby inform us that TYRU has now made it's first sales of the PureScience range and the first 3 products targeting poultry and swine markets are now being actively marketed across MWI's worldwide sales channels. My view is that today's exit,at basement levels,by a significant holder(s) is providing a window of opportunity to acquire a stake in Tyratech at a seemingly attractive price.

You are correct of course vickythelad, YET, stock can be bought in quantity this morning at just 2.15 ! At such a low level TYRU could prove a rewarding medium term investment for new investors,as the company possesses a (currently overlooked)promising product pipeline.

On Friday, the federal authorities banned 19 chemicals long-used in antibacterial soaps, saying manufacturers failed to show they are safe and kill germs. “We have no scientific evidence that they are any better than plain soap and water,” Dr Janet Woodcock, of the Food and Drug Administration’s drug centre, said in a statement. Makers of anti-bacterial soaps challenged the finding (AP) The Associated Press said that the decision primarily targets two once-ubiquitous ingredients - triclosan and triclocarban - that some limited animal research suggests can interfere with hormone levels and spur drug-resistant bacteria. The chemicals have long been under scrutiny, and a cleaning industry spokesman said most companies have already removed the now banned 19 chemicals from their soaps and washes. Follow CBC News

Stilo punters,as opposed to investors,want their jam today. They naturally are frustrated,hence the post results selling. Stilo have not yet reached the rainbows end,but that pot of gold seemingly awaits. Toshiba's was an important new contract, as they had earlier stated that Omnimark was particularly well suited to converting Japanese hieroglyphics.

I couldn't agree more with you,for I have been invested here since 2008/9,having bought in at just 1 pence. The results on Thursday could be interesting,should much focus be placed on future prospects.The strong endorsements of Stilo and in particular AuthorBridge by IBM over recent months must surely catch the eye of other global corporates who might well benefit from Stilo's market leading software.

The purpose of this synopsis is to notify industry that the United States Nuclear Regulatory Commission (U.S. NRC) intents to award a Purchase Order without providing for full or open competition under the authority of FAR 13.106-1 (b)(1)(i) "Soliciting from a Single Source." This notice of intent is neither a request for quotes nor a solicitation for offers. If awarded, the sole source purchase order will be issued to the following company: Stilo International Windmill Hill Business Park Whitehill Way, Swindon Wiltshire SN5 6QR United Kingdom The purpose of this acquisition is to obtain 100 AuthorBridge software licenses. AuthorBridge is a browser-based, enterprise Darwin Information Typing Architecture (DITA) compliant, web-based XML authoring tool. AuthorBridge was developed by Stilo and is an easy to use HTML editor that supports XML and is an integral component of the Review Management System (RMS). Several products were reviewed as part of the market research to find a DITA (Darwin Information Typing Architecture) compliant, web-based XML editor. The result of market research was that Stilo provides in their product, AuthorBridge, a unique combination of interoperability with IBM P8 Case Manager, on the fly translation from HTML to XML and back again, and an intuitive and very easy to use user interface, which all meets the current needs of the U.S. NRC.

The window of opportunity to buy STL shares at just 7 pence seems to be closing. 8 pence levels are looming imo,possibly in the next couple of weeks.

The resignation,by mutual agreement, of Richard Alsept, from his position as Director, CFO and Company Secretary of Stilo International, could be construed a bullish indicator,for it represents a further "clearing of the decks". Although the MMs reacted to the announcement with a further mark down in the SP,they do in fact remain keen to buy,at a premium and in size.